Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Current Liabilities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Total Current Liabilities for 12 consecutive years, with $8.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 86.86% year-over-year to $8.0 million, compared with a TTM value of $8.0 million through Sep 2025, down 86.86%, and an annual FY2024 reading of $7.0 million, up 50.71% over the prior year.
  • Total Current Liabilities was $8.0 million for Q3 2025 at Avalo Therapeutics, down from $9.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $215.7 million in Q1 2024 and bottomed at $4.6 million in Q4 2023.
  • Average Total Current Liabilities over 5 years is $32.6 million, with a median of $19.0 million recorded in 2021.
  • The sharpest move saw Total Current Liabilities surged 910.39% in 2024, then plummeted 97.4% in 2025.
  • Year by year, Total Current Liabilities stood at $19.9 million in 2021, then grew by 11.19% to $22.1 million in 2022, then plummeted by 79.12% to $4.6 million in 2023, then skyrocketed by 50.71% to $7.0 million in 2024, then increased by 14.54% to $8.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for AVTX at $8.0 million in Q3 2025, $9.3 million in Q2 2025, and $5.6 million in Q1 2025.